Buy Alert on XFOR: Guggenheim Highlights Mavorixafor as a Game-Changer in Rare Blood Disorders

Guggenheim starts coverage on X4 Pharmaceuticals with a Buy rating and $12 price target, highlighting major potential from mavorixafor in rare blood disorders like WHIM syndrome and chronic neutropenia.